Startup profile · funding coverage

Anagram Therapeutics

Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.

Stage

See coverage

Status

private

Coverage

full

Why Anagram Therapeutics is interesting

Developing novel therapeutics is capital-intensive and high-risk, requiring sustained funding through clinical milestones. Anagram's raise provides the runway to advance its programs. - The reopening exit market improves biotech's funding outlook. - Investors are selectively backing validated science over platform hype. - Large therapeutics rounds anchor the broader life-sciences ecosystem. Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.

Key facts

Disclosed financing: $250M
Covered in 1 Venture Capital Tracker article(s)

Industries

AI & Machine Learning Healthtech Biotech & Life Sciences

Industry hub pages are rolling out from our fund-derived baseline taxonomy.